HART Tests for Patients Video
Prevencio is Revolutionizing Blood Tests For Cardiovascular Disease —
POWERED BY ARTIFICIAL INTELLIGENCE (AI)
Preventing the Preventable
Prevencio's value proposition is "Preventing the Preventable" — That is, preventing unnecessary procedures and related side effects, as well as improving patient outcomes and clinical trials through more accurate blood tests for Cardiovascular Disease conditions.
Growing Product Pipeline Based Upon Novel Approach
Prevencio's patent-pending use of Multi-Proteomic Biomarkers, Clinical Variables, AI, and Proprietary Algorithms have delivered a Product Pipeline of seven (7) tests with more in development.
Cardiovascular Disease (CVD) kills more people each year than all forms of cancers combined.
1 of every 3 deaths
in the U.S.
Inaccurate Diagnostics are hindering timely
Invasive Diagnostic Procedures also come with unnecessary risks.
Doctors and Researchers need a low-cost, safe solution to improve diagnosis and risk stratification of Cardiovascular Disease (CVD) conditions such as Heart Attack, Stroke, Cardiovascular Death, Coronary Artery Disease (CAD), Peripheral Artery Disease (PAD), Aortic Stenosis (AS), Amputation Risk, and Acute Kidney Injury (AKI).
Leading Cause of Death & Growing
Cardiovascular disease is the leading global cause of death, accounting for more then 17.9 million deaths per year in 2015, a number that is expected to grow to more than 23.6 million by 2030.
ER visits for
Chest Pain Cases Found to be Cardiac-Unrelated
Annual Number of Inpatient Cardiac Caths in U.S.
Needless Cardiac Catheterizations Every Year
Prevencio employs Artificial Intelligence to interrogate well-characterized clinical data sets to produce novel, multi-protein, algorithmically-scored tests.
Clinical Accuracy for Patients & Doctors
Prevencio's HART CADhs Test
(AUC = 0.85) is significantly more accurate than Standard-of-Care Stress Tests
(AUC = 0.52) for diagnosing Coronary Artery Disease.
Value to Clinical Trials
Prevencio's HART CVE Test
can assess pre-drug/post-drug effects on composite of heart attack, stroke, & cardiac death. May also assist in Clinical Trial Enrichment by identifying high risk vs. low risk patients.
Attn Rhonda Rhyne
6424 Lake Washington Blvd NE, #13
Kirkland, WA 98033
\\ Tel: 425-576-1200
“I'm a testimonial. Click to edit me and add text that says something nice about you and your services.”
"There is a huge unmet need to accurately diagnose the presence of cardiovascular and peripheral arterial diseases. Though single biomarker tests have helped to refine diagnosis and prognosis, it is clear the future will be with a multiple biomarker approach supported by cutting-edge machine learning. The data generated using Prevencio HART tests show clear evidence that we can better diagnose and risk stratify cardiovascular events (CVE; Inclusive of heart attack, stroke, and death), coronary artery disease (CAD), peripheral artery disease (PAD), aortic stenosis (AS) and amputation (AMP) risk and Acute Kidney Injury (AKI). These tests could initiate therapy and lifestyle change earlier, possibly prevent complications such as heart attacks, and with earlier and more effective treatment simultaneously improve patient quality of life. In addition to the opportunity for more appropriate care of patients, we believe HART tests could benefit cardiac clinical trials by saving time and thereby lowering overall trial costs."
”Although we have a few single biomarkers for use in the emergency department, the development of a multi-analyte diagnostic test incorporating clinical patient variables and algorithmic analysis would be invaluable and represents a
game-changer for clinical medicine.”
"Single protein tests, specifically troponin and BNP, revolutionized patient care but, due to the multifactorial issues related to cardiac disease, single protein kits have inherent limitations.”
“With increased understanding of the human plasma proteome, I am excited to support Prevencio in developing a multi-analyte algorithmic analyses protein test which has the potential to surpass the clinical value of any single analyte cardiac biomarker test.”
James Januzzi, MD, FACC
Cardiac Biomarker & Guidelines
Key Opinion Leader
Frank Peacock, MD
Emergency Medicine Cardiac Biomarker Key Opinion Leader
Alan Maisel, MD
Key Opinion Leader